BioCentury
ARTICLE | Company News

CytoDyn, Progenics deal

October 22, 2012 7:00 AM UTC

CytoDyn completed its acquisition of Progenics' PRO 140 and related assets to treat HIV/AIDS infection for $3.5 million in cash. Progenics is also eligible for a $1.5 million milestone payment upon t...